Core Insights - Ignite Proteomics LLC has successfully transferred the Proprietary Laboratory Analyses (PLA) code 0249U from Theralink Technologies, enhancing its capabilities in proteomic diagnostics for breast cancer [1][10] - The PLA code 0249U is recognized in the Medicare Clinical Laboratory Fee Schedule and is reimbursed at $2,219.13, indicating its significance among high-complexity diagnostic assays [2][10] - The integration of the PLA code positions Ignite Proteomics to lead in proteomic diagnostics and accelerate innovation in precision oncology [3] Company Overview - Ignite Proteomics specializes in advanced Reverse Phase Protein Array (RPPA) technology for cancer diagnostics, operating under a CLIA-certified, CAP-accredited, and NY State-approved laboratory [7] - The company aims to bridge the gap left by gene-focused methods by helping physicians match patients with suitable targeted therapies [7] - IMAC Holdings, the parent company, is committed to improving patient outcomes through innovative healthcare solutions and is in the process of rebranding to IMAC Holdings, Inc., DBA Ignite Sciences, Inc. [8] Diagnostic Methodology - Ignite's proteomic assay measures functional protein activity in breast tumors, providing oncologists with data on how patients might respond to targeted therapies [3] - This method differs from standard genomic tests by identifying active proteins, potentially improving treatment outcomes for patients [6][12] - The establishment of a dedicated PLA code allows for clearer reimbursement pathways, avoiding confusion associated with generic billing codes [5][10]
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay